Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Gut

Volumn 65, Issue 7, 2016, Pages 1132-1138

  Ben Horin, Shomron ^a   Yavzori, Miri ^a   Benhar, Itai ^a   Ella Fudim, Ella ^a   Picard, Orit ^a   Ungar, Bella ^a   Lee, Soo Young ^b   Kim, Sung Hwan ^b   Eliakim, Rami ^a   Chowers, Yehuda ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; BIOSIMILAR AGENT; DRUG ANTIBODY; EPITOPE; EXCIPIENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOMER; REMICADE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIBODY; CT-P13; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CHILD; COLITIS; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; CROHN DISEASE; DEGLYCOSYLATION; DIALYSIS; DRUG CROSS REACTIVITY; DRUG INHIBITION; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FILTRATION; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN PURIFICATION; SERUM; SIZE EXCLUSION CHROMATOGRAPHY; ULCERATIVE COLITIS; BLOOD; CHEMISTRY; CROSS REACTION; GLYCOSYLATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADALIMUMAB; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; CROSS REACTIONS; GASTROINTESTINAL AGENTS; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84973896889     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309290     Document Type: Article

References (22)

1. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
3. McKeage K. A Review of CT-P13: An Infliximab Biosimilar. BioDrugs 2014;28:313-21.
4. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
5. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
6. European Medicines Agency: Inflectra. European public assessment report. http:// www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002778/human-med-001677.jsp&mid=WC0b01ac058001d1242013 (accessed 6 Feb 2014).
7. Danese S, Gomollon F, Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7:586-9.
8. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars. AAPS J 2014;16:22-6.
9. Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014;8:431-5.
10. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
11. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
12. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8.
13. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011;60:41-8.
14. Ben-Horin S, Mazor Y, Yanai H, et al. The decline of anti-drug antibody titers after discontinuation of anti-TNFs: Implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012;35:714-22.
15. Rinaudo-Gaujous M, Paul S, Tedesco ED, et al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013;38:914-24.
16. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-83.
17. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs 2014;6:1163-77.
18. Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:1172-83.
19. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:349-58.
20. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635-46.
21. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
22. FrederiksenM.T. AinsworthM.A. BrynskovJ. et alAntibodies against infliximab are associated with De Novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBDInflamm Bowel Dis.2014201714-1721